Impact of the initial decline in estimated glomerular filtration rate on the risk of new-onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated with sodium-glucose co-transporter-2 inhibitors.
Yi-Hsin ChanShao-Wei ChenTze-Fan ChaoYi-Wei KaoChien-Ying HuangPao-Hsien ChuPublished in: Diabetes, obesity & metabolism (2021)
A pronounced eGFR decline of more than 30% following SGLT2i treatment was associated with adverse cardiovascular or renal events among patients with T2D.